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Abstract. Objective: In this mini-review 
we describe the behavior of polymorpho-
nuclear leukocyte (PMN) membrane fluidity 
and of PMN cytosolic Ca2+ concentration in 
some chronic and acute clinical conditions. 
Methods: PMN membrane fluidity was eval-
uated employing the fluorescent probe Fura-
2AM, and PMN cytosolic Ca2+ concentration 
was evaluated using the fluorescent probe 
TMA-DPH. Results: From the determina-
tion of these two parameters investigated on 
resting PMNs, an almost constant increase in 
PMN cytosolic Ca2+ concentration in chronic 
clinical conditions, such as vascular athero-
sclerotic disease with and without diabetes 
mellitus, essential hypertension, chronic kid-
ney disease, and diabetes mellitus of both 
types, and a decrease in PMN membrane flu-
idity in acute clinical conditions, such as ju-
venile acute myocardial infarction and acute 
ischemic stroke, are evident. Conclusion: The 
possible reasons for this different behavior 
are analyzed on the basis of pathophysiologi-
cal considerations.
Introduction
In the past decades many papers of our 
group have investigated the functional aspect 
of polymorphonuclear leukocytes (PMNs) in 
the following clinical conditions: vascular 
atherosclerotic disease, essential hyperten-
sion, chronic kidney disease (CKD), diabetes 
mellitus (DM), acute ischemic stroke (AIS), 
and juvenile acute myocardial infarction 
(AMI).
PMNs attract microrheological and meta-
bolic attention because these cells, with their 
geometric and biological characteristics, sig-
nificantly influence the microvascular flow 
and this effect is due in particular to their 
adhesion to the endothelial cells, to their en-
trapment, or to their spontaneous activation. 
At the same time many papers have instead 
focused on the role played by the leukocyte 
count in the above-mentioned clinical condi-
tions [1, 2, 3, 4, 5, 6, 7, 8, 9 ,10, 11, 12, 13, 
14].
Regarding PMNs, our attention has been 
especially directed towards the examination 
of the PMN membrane fluidity and the PMN 
cytosolic Ca2+ concentration, both under 
basal condition and after in vitro activation 
with chemotactic agents, such as 4-phorbol, 
12-myristate, 13-acetate (PMA), and N-for-
myl-methionyl-leucyl-phenylalanine (fMLP).
PMN membrane fluidity, related in par-
ticular to the membrane lipid and protein 
composition, is a major component of the 
PMN deformability, influenced also by cyto-
solic Ca2+ concentration. These two param-
eters affect the functional aspects of PMNs, 
considering that membrane fluidity regulates 
some functions of PMNs, such as phagocy-
tosis, and that the increase in cytosolic Ca2+ 
concentration is considered a marker of 
PMN activation. It must be underlined that 
the cytosolic calcium concentration is related 
to the activity of the membrane pumps and 
that this activity is influenced by the mem-
brane fluidity [15, 16].
According to our experience, at baseline 
these two PMN parameters show a different 
behavior in chronic and acute clinical condi-
tions (Table 1).
Chronic clinical conditions
In chronic vascular atherosclerotic dis-
ease (VAD) with and without type 2 diabetes 
mellitus (DM2), we noted [17, 18, 19] an in-
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crease in PMN cytosolic Ca2+ concentration 
without any significant variation of the PMN 
membrane fluidity. This trend was confirmed 
when the VAD subjects, with and without 
DM2, were also subdivided according to 
the monovascular or polyvascular localiza-
tion of the disease. In addition, it has to be 
emphasized, while in normal controls and in 
VAD subjects without DM we found a sig-
nificant positive correlation between PMN 
membrane fluidity and PMN cytosolic Ca2+ 
concentration, this finding was not observed 
in the group of VAD subjects with type 2 DM 
[18]. The same results have been noted in hy-
pertensive [20, 21, 22] and in CKD patients 
[23, 24, 25, 26]. At baseline, in subjects with 
essential hypertension we found an increase 
in PMN cytosolic calcium content only. In 
our survey, in essential hypertension none of 
these two PMN parameters was correlated 
with systolic and diastolic blood pressure 
values; also in conservatively treated CKD 
patients, none of these PMN parameters was 
correlated with blood urea nitrogen or serum 
creatinine.
In diabetic disease, the behavior of the 
PMN membrane fluidity and cytosolic Ca2+ 
concentration seems to be controversial [27, 
28, 29, 30], although the examination of 
these parameters suggests that they are espe-
cially dependent on the extent of the record of 
cases and on the glicometabolic pattern. Re-
garding this last aspect, we know in fact that 
the PMN dysfunction results significantly 
correlated to the PMN metabolic profile that 
characterizes diabetes mellitus. This profile 
regards in particular the decreased activity of 
phosphofructokinase, and thus the glycolytic 
pathway, the increase in the hexose mono-
phosphate shunt, the activation of the polyol 
pathway, and thus the increased PMN con-
tent of sorbitol. Recently [31], re-examining 
a large group of diabetics of both types, we 
found that PMN membrane fluidity does not 
discriminate diabetics of both types from 
normal controls while PMN cytosolic Ca2+ 
content is especially significantly increased 
in patients with type 1 diabetes (Table 1).
Acute clinical conditions  
(ischemic stroke and juvenile 
myocardial infarction)
PMN membrane fluidity and PMN cy-
tosolic Ca2+ concentration seem to show a 
particular trend in acute clinical conditions, 
such as acute ischemic stroke and juvenile 
acute myocardial infarction (Table 1).
We know that AIS is associated with 
brain infiltration of several types of inflam-
matory cells, including leukocytes [32], even 
if a direct action of leukocyte activity and 
inflammation in the ischemic lesion has not 
been demonstrated [14]. In AMI, the PMNs, 
besides being responsible for the inflamma-
tory processes, are involved in the decreased 
microcirculation flow leading to negative 
events and in particular to the no-reflow phe-
nomenon [33]. It has been demonstrated that 
PMNs also play a role in left ventricular re-
modeling after AMI [34].
In a first group of AIS subjects [35, 36, 
37], examined 48 – 72 hours after the onset 
of stroke, we noted that only PMN mem-
brane fluidity was significantly decreased in 
comparison with controls without any varia-
tion of the PMN cytosolic calcium concen-
tration. In a second group (unpublished data) 
we noted that the decrease of the PMN mem-
brane fluidity, besides being evident at the 
initial stage, was also present 30 days after 
the ischemic event; in these subjects we ob-
served, at the initial stage and after 30 days, 
an increase in the leukocyte count and in par-
ticular in the PMN count.
In subjects with juvenile AMI we ob-
served a decrease of PMN membrane fluid-
ity associated with a significant increase in 
cytosolic Ca2+ concentration; this finding 
persisted 12 months later [38]. At the initial 
stage of juvenile AMI, the leukocyte count 
Table 1. Behavior of the PMN membrane fluidity and of cytosolic Ca2+ con-
centration in chronic and acute clinical conditions (previously published per-
sonal data).
Chronic conditions PMN membrane 
fluidity
PMN cytosolic Ca2+ 
concentration
VAD with DM ↔ [17, 18, 19] ↑ [17, 18, 19]
VAD without DM ↔ [17, 18, 19] ↑ [17, 18, 19]
Hypertension ↔ [20, 21, 22] ↑ [20, 21, 22]
Chronic kidney disease ↔ [23, 24, 25, 26] ↑ [23, 24, 25, 26]
Diabetes mellitus ↔ [27, 28, 29, 30] ↑ [27, 28, 29, 30]
Acute conditions
Acute ischemic stroke ↓ [35, 36, 37] ↔ [35, 36, 37]
Young myocardial infarction ↓ [38] ↑ [38]
VAD = vascular atherosclerotic disease; DM = diabetes mellitus. 
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was increased in comparison with controls 
and this increase was also evident after 12 
months; the same trend was also noted for 
the PMN count [38].
Conclusive and pharmacological 
consideration
While the increase of PMN cytosolic 
Ca2+ concentration may be explained by a 
functional abnormality of PMN Ca2+ ATPase 
activity, the decrease of PMN membrane flu-
idity is probably dependent on the alteration 
of the lipid and protein composition of the 
PMN membrane that modifies the polariza-
tion degree of the fluorescent probe. In our 
research we employed the fluorescent probe 
TMA-DPH (1.4-(trimethylamino)-phenyl-
4-phenylhexatriene), a cationic derivative of 
DPH, that is localized at the lipid/water in-
terface region of the bilayer where it remains 
for up to 30 minutes. The data obtained using 
this fluorescent probe reflects in particular 
the membrane lipid fluidity that, partly influ-
enced by the cholesterol/phospholipid ratio, 
regulates the PMN deformability.
We suppose that the decrease in PMN 
membrane fluidity observed in juvenile AMI 
and AIS might be ascribed to the alteration of 
oxidative status, in particular to lipid peroxi-
dation and protein oxidation accompanying 
these events; the abnormal oxidative status 
contributes to the modification of the lipid 
ordering, especially in the outside part of 
the PMN membrane. In subjects with juve-
nile AMI in whom we investigated plasma 
lipid peroxidation, expressed as TBARS, 
and plasma protein oxidation, expressed as 
carbonyl groups, a marked increase in both 
parameters was found at the initial stage of 
AMI [39, 40]. The same behavior was pres-
ent in AIS patients, in whom the increase 
in lipid peroxidation and protein oxidation, 
besides being evident at admission and 24 
hours later [41], persisted for some months 
after the onset of AIS [42].
Also considering that PMN membrane 
fluidity and cytosolic Ca2+ concentration 
seem to have a particular behavior when ac-
tivation techniques are employed in vitro, it 
is useful to underline their trend as an indica-
tor of PMN dysfunction.
All these findings might suggest to 
choose the pharmacological treatment for 
each of these clinical conditions according 
to the molecules that are able to modulate or 
modify the PMN functional behavior, such 
as calcium channel blockers [43,44], pent-
oxifylline [45], prostacyclin analogs and mi-
metics [46], buflomedil [47], beta-blockers 
[48], and statins [49,50].
Furthermore, it must be underlined that 
in AMI subjects, monoclonal antibodies 
against β2-integrins (CD18 or CD11/CD18) 
were used to influence the functional activity 
of the PMNs [51, 52, 53, 54]. In AIS subjects 
an approach with monoclonal antibodies ver-
sus CD11/CD18 and CD11b/CD18 was em-
ployed instead [55, 56].
In conclusion, there is some information 
regarding the role of polymorphonuclear leu-
kocytes in several clinical conditions, and at 
the same time there is much data regarding 
the influence of some molecules on some 
characteristics of these circulating cells; in 
this brief report based on our experience 
in the microrheological field, we have pre-
sented the behavior of these two PMN pa-
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